Farhang Sara, Ghaemmaghami Mehrdad, Shafiee-Kandjani Ali Reza, Noorazar Seyed Gholamreza, Veling Wim, Malek Ayyoub, Somi Mohammad Hossein, Bruggeman Richard, Alizadeh Behrooz Z
University Medical Center Groningen, University Center for Psychiatry, Rob Giel Research Center, University of Groningen, Groningen, Netherlands.
Research Center of Psychiatry and Behavioral Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Front Psychiatry. 2021 Feb 10;12:627960. doi: 10.3389/fpsyt.2021.627960. eCollection 2021.
Most of our knowledge about the etiology, course, treatment, and outcome of schizophrenia spectrum and other psychotic disorders stems from Western countries. Data from populations living in other geographical areas and low- and middle-income countries, with different genomes (ethnicity) and exposomes (e.g., culture and social support, drugs of abuse, religion), will add to our knowledge of this complex disorder. The Azeri Acute phase/Recent onset psychosis Survey (ARAS) has been initiated to study the course of the disorder in patients with recent-onset psychosis using validated diagnostic tools and a comprehensive outcome monitoring system, aiming to reveal indicators for understanding the risk and resilience factors and for choosing the best-personalized treatment strategy. All participants will be evaluated for clinical signs and symptoms as well as risk and resilience factors and will be followed up for 1, 3, and 5 years for outcomes in several domains. A hierarchical cluster method will be applied to identify the number of clusters for each outcome. Defined models will be applied to assess the predictive value of cognition on symptomatic and functional outcomes at follow-up. The ARAS cohort will yield significant academic- (research and education) and care-related achievements. ARAS data and experience will have value both in being a useful model for other parts of this region and in an expansion of the currently available knowledge.
我们关于精神分裂症谱系及其他精神障碍的病因、病程、治疗和预后的大部分知识都源于西方国家。来自其他地理区域以及低收入和中等收入国家、具有不同基因组（种族）和暴露组（如文化和社会支持、滥用药物、宗教）人群的数据，将增进我们对这种复杂疾病的了解。阿塞拜疆急性期/近期起病精神病调查（ARAS）已经启动，旨在使用经过验证的诊断工具和全面的结局监测系统，研究近期起病精神病患者的疾病病程，目的是揭示有助于理解风险和复原力因素以及选择最佳个性化治疗策略的指标。所有参与者将接受临床体征和症状以及风险和复原力因素的评估，并将在1年、3年和5年时对多个领域的结局进行随访。将应用层次聚类方法来确定每个结局的聚类数量。将应用定义的模型来评估随访时认知对症状性和功能性结局的预测价值。ARAS队列将产生重大的学术（研究和教育）及与护理相关的成果。ARAS的数据和经验不仅对该地区其他地方是一个有用的模型，而且对扩展现有知识也具有价值。
